Company type | Public |
---|---|
Industry | Pharmaceuticals |
Predecessor | Cardinal Health PTS |
Founded | 2007 |
Headquarters | Somerset, New Jersey, U.S. |
Number of locations | 52 (2023) |
Key people | Alessandro Maselli (President, CEO & Director), Matti Masanovich (CFO) |
Services | Drug pre-formulation, formulation, analytical testing, clinical and commercial manufacturing, clinical packaging and supply chain, regulatory consulting |
Revenue | US$4.26 billion (2023) |
US$−163 million (2023) | |
US$−256 million (2023) | |
Total assets | US$10.8 billion (2023) |
Total equity | US$4.61 billion (2023) |
Number of employees | 17,800 (2023) |
Website | catalent |
Footnotes / references Financials as of June 30, 2023[update].[1] |
Catalent, Inc. (Catalent Pharma Solutions) is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people,[2] including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue.[3]
Catalent was formed in April 2007 when affiliates of the Blackstone Group L.P. acquired the core of the pharmaceutical technologies and services (PTS) segment of Cardinal Health, Inc.[4] Cardinal Health created PTS through a series of acquisitions starting with R.P. Scherer Corporation in 1998.[5]
In 2014, Catalent became a public company, listed on the New York Stock Exchange.
In 1996, Cardinal Health acquired PCI (Headquarters: Philadelphia, Pennsylvania).[6] PCI (Packaging Coordinators Inc.) is a pharmaceutical contract packing service for commercial and clinical packaging.[7]
In 1998, Cardinal Health acquired R.P. Scherer Corporation (Headquarters: Troy, Michigan).[8] Robert Pauli Scherer founded the R.P. Scherer Corporation to commercialize his innovation of softgel encapsulation using the rotary die production process.[9] The following year, in 1999, Cardinal Health acquired Automatic Liquid Packaging, Inc. (Headquarters: Woodstock, Ill.),[6] whose Blow-Fill-Seal Technology allowed Cardinal to enter the sterile product market.[9]
In 2001, Cardinal Health acquired International Processing Corporation, a company that was renowned for its expertise in oral modified-release dosage form development and manufacturing. In 2002, Cardinal Health acquired Magellan Laboratories Inc., a company that specialized in product development expertise.[6] In 2003, Cardinal Health acquired Gala Biotech (Headquarters: Madison, Wisconsin).[6] In the same year, Cardinal Health also acquired Intercare Group PLC, broadening its global capabilities in Europe.[6]
From 2004 to 2006, Cardinal Health further expanded its reach in biotechnology and pharmaceutical markets through multiple acquisitions.[6]
In 2007, the pharmaceutical technologies and services segment of Cardinal Health was purchased by Blackstone Group and re-branded as Catalent Pharma Solutions.[4]
In 2012, Catalent acquired Aptuit, a clinical supply company. As part of the deal, Catalent gained three sites in the US, two in the UK, and one in Singapore.[10] Catalent also acquired all remaining shares for the R.P Scherer site in Eberbach, Germany.[8][11][12] In 2013, Catalent continued the global expansion of its Softgel capabilities through a joint venture with Zhejiang Jaing Yuan Tang Biotechnology Co, a China-based company, and Relthy Laboratories in Brazil.[13]
Catalent announced its initial public offering in July 2014. After raising more than $870 million, Catalent became a publicly traded company on the New York Stock Exchange (NYSE).[14] The company priced its 42.5 million shares of common stock at $20.50 apiece, with a market capitalization of $2.4 billion. The shares began trading on the NYSE on 31 July 2014, under the ticker symbol CTLT.[14]
In November 2014, Catalent announced it had acquired Micron Technologies, a provider of particle size engineering technologies.[15] The acquisition allowed Catalent to expand its portfolio of drug delivery technologies.[15]
In 2016, Catalent licensed the anti-body drug conjugate (ADC) to Triphase Accelerator to help with oncology development,[16] and bought Pharmatek Laboratories to add spray drying to their manufacturing capabilities.[17] In September 2017, Catalent agreed to acquire Cook Pharmica for $950 million, allowing Catalent to expand their biologic manufacturing.[18] In July 2018, Catalent extended their work with Juniper Pharmaceuticals with a $133 million deal.[19]
Alessandro Maselli was appointed as president and chief operating officer in 2019, a newly created position within Catalent.[20] In March, 2019, Catalent invested more than $27 million to commercialize Zydis Ultra. The investment includes new Zydis lines; changes to one of their facilities in Swindon, UK; and a custom suite for commercial equipment.[21] Later in 2019, Catalent partnered with GB Sciences to develop a cannabinoid-derived medicine for Parkinson's disease utilizing the Zydis delivery method.[22]
In April 2019, Catalent agreed to acquire Paragon Bioservices Inc for $1.2 billion to expand its gene-therapy manufacturing capabilities.[23] The deal was completed in May 2019 and included an agreement with Sarepta Therapeutics, a gene therapy manufacturer.[24] As of October 2019, Paragon's employee numbers have almost doubled since the April acquisition.[25]
In June 2019, Catalent acquired Bristol-Myers' European launch pad to expand its global CDMO.[26]
In January 2020, Catalent purchased a manufacturing facility located in Anagni, Italy, from Bristol-Myers Squibb, to manufacture and package biologic and oral solid dose products for multiple companies.[27] In February 2020, Catalent agreed to acquire MaSTherCell, a Belgian gene and cell therapy manufacturer, for $315 million. The acquisition allows Catalent to expand into cell therapy development.[28][29]
In 2020, Catalent partnered with multiple drugmakers, including Pfizer, Johnson & Johnson,[30] AstraZeneca,[31] and Moderna[32] to provide manufacturing, vial filling and packaging capabilities for COVID-19 vaccine candidates.[33][34] In the partnership with AstraZeneca, Catalent will provide manufacturing from its Maryland facility and vial filling and packaging from its Italian facility.[35] Catalent also partnered with ViralClear to manufacture a COVID-19 treatment candidate at Catalent's St. Petersburg facility.[36] Also in 2021, Catalent acquired German gene therapy development firm Rheincell Therapeutics.[37]
In August 2021, Catalent announced plans to acquire nutritional supplement company Bettera Holdings LLC for $1 billion. The deal will allow Catalent to manufacture vitamins, minerals and supplements in gummy form.[38]
In October 2021, Catalent opened a 6,000 square-meter clinical supply facility in Shiga, Japan.[39]
In October 2022, Catalent announced a $12M expansion at a Kansas City, MO facility.[40]
In January 2023, Catalent partnered with Sarepta Therapeutics to manufacture delandistrogene moxeparvovec (SRP-9001). Sarepta's most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy (DMD).[41][42][43]
In February 2024, Novo Holdings A/S agreed to acquire Catalent for $16.5 billion. On completion, Novo Nordisk would acquire three manufacturing facilities from parent Novo Holdings for $11 billion to scale up production to meet the demand of its obesity and diabetes drugs Wegovy and Ozempic respectively.[44][45]
# | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.85bn | 2.08bn | 2.46bn | 2.52bn | 3.09bn | 3.998bn | 4.828bn | 4.863bn |
Total Current Assets | 3.09bn | 2.45bn | 4.53bn | 6.18bn | 7.78bn | 9.112bn | 10.507bn | 10.777bn |
Net Operating Cash Flow | 155.3M | 299.5M | 374.5M | 247.7M | 440.3M | 0.585bn | 0.519bn | −0.256bn |